Study Title: Liver Cancer (Hepatocellular Carcinoma): Sorafenib vs Placebo as Adjuvant Treatment
Category: Cancer, General
Currently accepting participants?
Not at this time.
Principal Investigator: Thomas Malpass
Study Coordinator: Andrea Jacks
Phone: 206-625-7373 Ext.63979
Email: andrea.jacks@vmmc.org
What is the Liver Cancer (Hepatocellular Carcinoma): Sorafenib vs Placebo as Adjuvant Treatment study?
Please visit clinicaltrials.gov and enter the ID NCT00692770
Who can participate?
Study Summary:
The study will include subjects diagnosed for the first time with HCC. After surgery or ablation, subjects will be randomized to sorafenib or placebo.
Detailed Study Description:
Please visit clinicaltrials.gov and enter the ID NCT00692770
Study Design: Interventional, Blinded
Phase of Study: Phase III
Study Type: Interventional
Condition or Study Focus: Hepatocellular Carcinoma (Liver Cancer)
Intervention Type: Drug
Intervention Name: Sorafenib Tablets
Gender: Male and Female
Age group: Interventional
Sponsor: Bayer
Other studies in this category include:
Studies currently accepting study participants:
Studies currently not accepting study participants:
- A Randomized Phase III Trial of Concurrent Accelerated Radiation and Cisplatin Versus Concurrent Accelerated Radiation, Cisplatin, and Cetuximab (C225) Followed by Surgery for Selected Patients for Stage III and IV Head and Neck Carcinomas
- AMC045: HIV-Associated Anal Cancer
- Investigating Proteomic Biomarkers of Radiation Therapy Outcome: A Pilot Study
- Investigational drug vs. Placebo for Patients with Renal Cell Carcinoma (Kidney Cancer) at High Risk of Recurrence after Surgery
- Kidney Cancer (Renal Cell Carcinoma): Study Comparing Bevacizumab + Temsirolimus Vs Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects (INTORACT)
- Liver Cancer (Hepatocellular Carcinoma): Sorafenib vs Placebo as Adjuvant Treatment
- Liver Cancer (Hepatocellular Carcinoma): Study Of Sunitinib Malate Versus Sorafenib In Patients With Inoperable (Advanced or Metastatic) Liver Cancer
- Liver Cancer (Hepatocellular Carcinoma): TACE for Intermediate Stage
- MK0646 for Patients with Advanced Cancer
- Newly diagnosed, untreated ovarian or peritoneal cancer (GOG 0218)
- Radiation Therapy and Either Capecitabine or Fluorouracil With or Without Oxaliplatin Before Surgery in Treating Patients With Resectable Rectal Cancer
- Sorafenib v. Sunitinib v. Placebo for High Risk Renal Cell Carcinoma Patients
- Trial of FOLFOX with or without cetuximab for colon cancer
- Use of Human Corticotropin-Releasing Factor (hCRF) to Control Brain Swelling (edema) in Brain Tumor Patients
- Weekly IV of Hymcamtin in Combination with Carboplatin as Second Line Therapy in Potentially Platinum-Sensitive Reaplased Ovarian Cancer